In addition, treatment with the GluN2B subunit-specific NMDAR antagonist ifenprodil showed a decreased cell survival and cell migration resulting in a more pronounced radiosensitizing effect as compared to MK801, highlighting the clinical potential of GluN2B subunit-specific NMDAR-antagonists and CREB-mediated downstream signaling in optimizing RT in glioblastoma treatment. The gene discussed is GRIN2B; the disease is glioblastoma.